LB 11058 is a novel parenteral cephalosporin with a C-3 pyrimidinyl-substituted vinyl sulfide group and a C-7 2-amino-5-chloro-1,3-thiazole group. This study evaluated the in vitro activity and spectrum of LB 11058 against 1,245 recent clinical isolates, including a subset of gram-positive strains with specific resistant phenotypes. LB 11058 was very active against Streptococcus pneumoniae. The novel cephalosporin was 8-to 16-fold more potent than ceftriaxone, cefepime, or amoxicillin-clavulanate against both penicillin-intermediate and -resistant S. pneumoniae. LB 11058 was also very active against both ␤-hemolytic streptococci (MIC at which 90% of isolates were inhibited [MIC 90 ], <0.008 g/ml) and viridans group streptococci (MIC 90 , 0.03 to 0.5 g/ml), including penicillin-resistant strains. Among oxacillin-susceptible Staphylococcus aureus, LB 11058 MIC results varied from 0.06 to 0.25 g/ml (MIC 50 , 0.12 g/ml), while among oxacillin-resistant strains LB 11058 MICs varied from 0.25 to 1 g/ml (MIC 50 , 1 g/ml). Coagulase-negative staphylococci showed an LB 11058 susceptibility pattern similar to that of S. aureus, with all isolates being inhibited at <1 g/ml. LB 11058 also showed reasonable in vitro activity against Enterococcus faecalis, including vancomycin-resistant strains (MIC 50 , 1 g/ml), and Bacillus spp. (MIC 50 , 0.25 g/ml); however, it was less active against Enterococcus faecium (MIC 50 , >64 g/ml) and Corynebacterium spp. (MIC 50 , 32 g/ml). Against gram-negative pathogens, LB 11058 showed activity against Haemophilus influenzae (MIC 90 , 0.25 to 0.5 g/ml) and Moraxella catarrhalis (MIC 90 , 0.25 g/ml), with MICs not influenced by ␤-lactamase production. In conclusion, LB 11058 demonstrated a broad antibacterial spectrum and was highly active against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci. . Comparator agents were purchased from Sigma Chemical Co. (St. Louis, Mo.) or obtained from their respective manufacturers in the United States. A total of 31 comparators were evaluated, depending upon the species tested. These compounds included ␤-lactams (penicillins, cephalosporins, penicillin-␤-lactamase inhibitor combinations, a monobactam, and a carbapenem), fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole, and several gram-positive-focused agents (macrolide-lincosamide-streptogramins, glycopeptides, and oxazolidinones).
Gram-positive bacterial pathogens have shown a remarkable ability to develop resistance to antimicrobial agents. Oxacillinand glycopeptide-resistant staphylococci, glycopeptide-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae and viridans streptococci have forced clinicians to seek alternative treatments for patients with serious gram-positive infections (1, 2, 3, 11, 15, 16) .
Oxacillin-resistant Staphylococcus aureus (MRSA) represents an important worldwide problem, and its prevalence may vary significantly from hospital to hospital. Data from the global SENTRY Antimicrobial Surveillance Program and other surveillance programs revealed a high and increasing prevalence of this pathogen in the United States, Latin America, and several regions of Europe (5; European Antimicrobial Resistance Surveillance System [http://www.earss.rivm.nl], accessed 24 September 2003). Over the past few years, MRSA has acquired stable resistance to most clinically available antimicrobial agents, and therapeutic options have been limited to the glycopeptides (vancomycin and teicoplanin) and, more recently, quinupristin-dalfopristin and linezolid (4, 7) . However, clinical isolates with reduced susceptibilities to these latter compounds have recently been described in several regions of the world (5, 7, 13) . Most MRSA isolates show resistance to virtually all ␤-lactams by production of penicillinase and a low-affinity penicillin-binding protein (PBP) called PBP 2a.
␤-Lactams with relatively high affinities for PBP 2a, such as penicillin, ampicillin, and amoxicillin, combined with ␤-lactamase inhibitors have demonstrated in vitro and in vivo anti-MRSA activities (10) . However, the addition of critical amounts of ␤-lactamase inhibitor are necessary to successfully treat these infections. Thus, ␤-lactams must combine both high affinity for PBP 2a and stability against degradation by staphylococci penicillinase to be considered for clinical use against infections caused by this pathogen (2, 12) .
S. pneumoniae is the most commonly identified bacterial cause of community-acquired pneumonia, otitis media, and meningitis, and it is a frequent pathogen in bacteremia (6, 21) . Morbidity and mortality may be high among patients with bacteremia and meningitis, especially when appropriate antimicrobial therapy is delayed. The emergence of S. pneumoniae with antimicrobial resistance has also become a matter of major concern. Resistance to penicillin and other antimicrobial agents has increased significantly in the last decade, making the treatment of serious infections very difficult, especially among children (15, 16, 19, 20, 22) .
LB 11058 is a novel parenteral cephalosporin with a C-3 pyrimidinyl-substituted vinyl sulfide group and a C-7 2-amino-5-chloro-1,3-thiazole group (Fig. 1 ). Preliminary studies have indicated that this compound has potent in vitro activity against gram-positive bacteria, including multidrug-resistant staphylococci and streptococci. This study was designed to confirm and extend the earlier presentations about the potency and spectrum of LB 
RESULTS
The in vitro activities of LB 11058 in comparison to numerous other antimicrobial agents against gram-positive bacteria are summarized in Table 1 . LB 11058 was very potent against ␤-hemolytic streptococci, with all strains being inhibited at Յ0.015 g/ml (MIC at which 90% of isolates were inhibited [MIC 90 ], Յ0.008 g/ml). LB 11058 was the most potent compound tested against S. pneumoniae. Against S. pneumoniae, LB 11058 activity varied according to the susceptibility to penicillin. Penicillin-susceptible strains (MIC 90 , Յ0.008 g/ml)
were very susceptible to LB 11058, while penicillin-intermediate strains (MIC 90 , 0.06 g/ml) and penicillin-resistant strains (MIC 90 , 0.12 g/ml) showed slightly higher LB 11058 MIC results (0.06 to 0.25 g/ml). The novel cephalosporin was 8-to 16-fold more potent than ceftriaxone, cefepime, or amoxicillinclavulanate against both penicillin-intermediate and -resistant strains. Penicillin-susceptible strains were very susceptible to LB 11058 and most antimicrobial agents evaluated, except for the macrolides (92.2 to 93.1% susceptible).
Similarly to S. pneumoniae, the susceptibilities of viridans group streptococci to LB 11058 varied according to the penicillin susceptibility. LB 11058 MICs ranged from Յ0.008 to 0.12 g/ml (MIC 90 , 0.03 g/ml) among penicillin-susceptible isolates and from 0.03 to 1 g/ml (MIC 90 , 0.5 g/ml) among penicillin-resistant strains. LB 11058 was also the most potent compound tested against viridans group streptococci, being 16-fold more potent than ceftriaxone or cefepime against this pathogen ( Table 1) .
LB 11058 showed potent in vitro activity against S. aureus, including oxacillin-resistant strains. Among oxacillin-susceptible strains, LB 11058 MIC results varied from 0.06 to 0.25 g/ml (MIC 90 , 0.25 g/ml), while MRSA LB 11058 MICs ranging from 0.25 to 1 g/ml (MIC 90 , 1 g/ml). LB 11058 (MIC 50 , 0.12 g/ml) was 32-fold more potent than ceftriaxone (MIC 50 , 4 g/ml), 16-fold more potent than cefepime (MIC 50 , 2 g/ml), and 4-fold more potent than oxacillin (MIC 50 , 0.5 g/ml) against oxacillin-susceptible isolates; only LB 11058 (MIC 90 , 1 g/ml), trimethoprim-sulfamethoxazole (MIC 90 , 1 g/ml), vancomycin (MIC 90 , 2 g/ml), quinupristin-dalfopristin (MIC 90 , 0.5 g/ml), and linezolid (MIC 90 , 2 g/ml) showed reasonable in vitro activities against oxacillin-resistant strains.
CoNS showed an LB 11058 susceptibility pattern similar to that shown by S. aureus, with all isolates being inhibited at Յ1 g/ml. LB 11058 (MIC 90 , 0.12 g/ml) was 32-fold more potent than ceftriaxone (MIC 90 , 4 g/ml) and 16-fold more potent than cefepime (MIC 90 , 2 g/ml) against oxacillin-susceptible CoNS strains. It was also very active against oxacillin-resistant strains (MIC 90 , 0.5 g/ml).
LB 11058 and ampicillin were the most active ␤-lactams evaluated against E. faecalis. Most E. faecalis isolates showed LB 11058 MICs of Յ4 g/ml, except for one isolate which was also resistant to linezolid and showed an LB 11058 MIC of Ͼ64 g/ml. All other cephalosporins evaluated showed poor activity against this pathogen. In general, vancomycin-resistant E. faecalis showed LB 11058 MIC results approximately fourfold higher than vancomycin-susceptible E. faecalis (MIC 50 , 0.25 and 1 g/ml, respectively). The activity of LB 11058 was higher against E. faecalis (MIC 90 , 2 g/ml) than against E. faecium (MIC 50 , Ͼ64 g/ml). Most E. faecium strains showed high MIC results for LB 11058 and most antimicrobial agents evaluated, except quinupristin-dalfopristin and linezolid.
LB 11058 (MIC 50 , 0.25 g/ml) and imipenem (MIC 50 , 0.12 g/ml) were the most potent ␤-lactams tested against Bacillus spp. (Table 1 ). The vast majority of Bacillus spp. isolates (85%) had LB 11058 MICs of Ն0.5 g/ml. Several other compounds showed reasonable activity against this pathogen, including clindamycin (MIC 50 , 0.5 g/ml), levofloxacin (MIC 50 , 0.12 g/ ml), ciprofloxacin (MIC 50 , 0.12 g/ml), teicoplanin (MIC 50 , Յ0.12 g/ml), and quinupristin-dalfopristin (MIC 50 , 0.5 g/ ml). On the other hand, Corynebacterium spp. showed de- Among the special subsets of isolates selected, all vancomycin-nonsusceptible strains (MIC, Ն4 g/ml) were inhibited at Յ1 g of LB 11058/ml (Table 1) . Also, linezolid resistance did not affect LB 11058 activity among staphylococci and streptococci. All four linezolid-resistant staphylococcal isolates had an 
